Keros Therapeutics Inc (KROS NASDAQ) stock market data APIs
$13.4807
0.04(0.3%)
as of June 30, 2025
Try our APIs with
free plan!
Keros Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Prev. Close
13.4807
Open
13.5243
High
13.594
Low
13.3613
52 wk Range
9.12-72.37
Market Cap
548 M
Shares Outstanding
40 615 K
Revenue
215 M
EPS
3.62
Beta
1.295
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Keros Therapeutics Inc data using free add-ons & libraries
Get Keros Therapeutics Inc Fundamental Data
Keros Therapeutics Inc Fundamental data includes:
- Net Revenue: 215 M
- EBITDA: -9 014 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: 0.0075
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Keros Therapeutics Inc News
New
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18. Zemansky noted that Keros has wra...
Noteworthy Monday Option Activity: KROS, RH, ADBE
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Keros Therapeutics Inc (Symbol: KROS), where a total of 6,554 contracts have traded so far,...
Keros Announces Return of $375 Million in Excess Capital to Stockholders
LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and c...
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
